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Abstract
Introduction: The development of peritoneal metastases is a signifi cant clinical issue in the treatment of abdominal cancers 
and is associated with poor prognosis. We have previously shown that ICAM-1-CD43 interaction plays a signifi cant role in 
tumor adhesion. However, an invasive phenotype is critical to establish tumor progression via cell associated and secreted 
proteases including matrix metalloproteinases. High metalloproteinases level signifi cantly enhanced metastasis phenotype 
on tumors, a detrimental effect on surgical outcome. We investigated the role of direct and indirect signaling between the 
mesothelium and the tumor cells in enhancing tumor invasion and possible therapeutic intervention.
Methods: Mesothelial cells were enzymatically derived from human omental tissue and implanted in 24 wells plates. 
Colorectal cancer cells were then introduced and allowed a direct and an indirect contact with the mesothelial layer. Anti-
ICAM antibodies, anti-CD43 antibodies, and heparin were used to block MMP production. Gelatin zymography was per-
formed on the supernatant to detect MMPs activity.
Results: MMP production was observed in mesothelial and tumor cells. Direct contact between cell types enhanced MMP9 
and 2 (p < 0.05). Indirect contact also stimulate MMPs but at a lower degree. ICAM-1 blocking antibodies attenuated MMP 
production in direct contact to that observed in the indirect. Heparin introduction achieved a similar outcome.
Conclusions: ICAM-1-CD43 interaction plays a vital role in tumor cells-peritoneum adhesion and invasion, which is 
manifested by the increased production of MMPs leading to tumor invasion and peritoneal loco-regional. Blocking this 
interaction with heparin can provide a new therapeutic option.
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Introduction
Colorectal cancer is the most common gastrointestinal cancer in the U.K. and U.S.A. It is estimated that 
30,000 new cases will be diagnosed in the U.K. and up to 150,000 in the U.S.A. each year (Cancer Research 
U.K., 2003; Jemal et al. 2003). Early detection and surgery remain the only curative treatment. However, 
even with surgery and adjuvant therapy, the fi ve year survival is around 60% (O’connell et al. 2004).
Nearly one third of patients with colorectal malignancies suffer from metastases at the time of 
diagnosis and about 50% who have early stage cancer may develop metastases (Midgley and Kerr, 
1999; Coutinho and Rocha Lima, 2003). In general, patient with peritoneal metastases have a poor 
prognosis (Sugerbaker et al. 1996) and out of those who undergo curative operations, around 25% could 
develop peritoneal recurrence (Brodsky and Cohen, 1991; Gunderson et al. 1985; Pestieau and 
Sugarbaker, 2000; Piso et al. 2007; Sugarbaker, 2007).
In order for peritoneal growth to happen, the tumor cells have to adhere to the mesothelium and/or the 
extracellular matrix, proliferate and then invade the submesothelial space to gain access to the circulation in 
order to achieve distance metastases (Schlaeppi et al. 1997). A number of cell adhesion molecules have been 
implicated to play a vital role in the adhesion process such as CD44, β1 integrin, ICAM-1 and CD43 (Alkhamesi 
et al. 2005b; Schlaeppi et al. 1997; Ziprin et al. 2004). However, induction of invasion is not clearly defi ned. 
The invasive process requires local proteolysis of the extracellular matrix, pseudopodial extension, and cell 
migration (Woodhouse et al. 1997). Both normal and malignant cells are capable of invading tissue because 
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they secret matrix metalloproteinases (MMPs) that 
degrade the extracellular matrix basement membrane 
(Aoudjit et al. 1998).
Matrix metalloproteinases are a family of func-
tionally related zinc-dependent proteinases that are 
capable of degrading all the components of the 
extracellular matrix. This group includes gelatin-
ases, collagenases and stromelysins (Li et al. 2002; 
Pross et al. 2002). The expression of MMPs is 
closely regulated by activating agents, including 
cytokines (IL-2, IL-4) and cell adhesion molecules 
of the integrin family (VCAM-1, ICAM-1) (Aoud-
jit et al. 1998). Moreover, their expression has been 
correlated with the invasive phenotype in a variety 
of human malignancies, including breast, colorec-
tal, hepatocellular, lung and prostate cancers (botos 
et al. 1996). Blocking MMPs activity specially 
MMP-2 and MMP-9 has been implicate to inhibit 
tumor invasion and angiogenesis (Albini et al. 
1991; Schnaper et al. 1993; Brown, 1997).
In this study, we investigate the effect of 
CD43-ICAM-1 interaction on MMP-2 and MMP-9 
activities and the possibility of a therapeutic 
intervention.
Methods
Cell lines
Human primary mesothelial cells were obtained 
from omental samples taken from patients undergoing 
elective abdominal operations, a procedure approved 
by St. Mary’s Hospital NHS Trust ethical commit-
tee. The cells were isolated as described by Styli-
anou et al. (Stylianou et al. 1990). Briefl y, the 
omental samples were digested in 0.25% trypsin 
(Life Technologies, Paisley, U.K.) for 20 min, on a 
tube rotator, at room temperature and then centri-
fuged at 800 g for six minutes. The pellet was then 
suspended in Media 199 with Earle’s balanced salts 
and L-glutamine containing 10% fetal calf serum 
(FCS) Life Technologies, Paisley, U.K.) supple-
mented with penicillin/streptomycin 100 μgml–1, 
insulin 5 μgml–1, apo-transferrin 5 μgml–1, hydro-
cortisone 0.4 μgml–1 (All Sigma Chemical Co., 
U.K.) and grown to sub-confl uence in 25 cm2 culture 
fl asks at 37 ºC in air with 5% CO2 and a complete 
change of media every 2–3 days. Immunocytochemical 
and morphological analysis of the mesothelial cells 
confi rmed purity of cell cultures. Positive staining 
for cytokeratin 18 and vimentin (both Chemicon, 
U.K.) together, with absence of von Willebrand 
Factor (CN Biosciences, U.K.), differentiated these 
cells from fi broblasts and endothelial cells, respec-
tively. The mesothelial cells used for each experi-
ment were at passage two.
The colorectal cell line (SW1222) used were 
obtained from the European Collection of Cell Cul-
tures (ECACC, CAMR, Wiltshire, U.K.) and grown 
to sub-confl uence in 75 cm2 culture fl asks using 
DMEM with glutamax (Life Technologies, Paisley, 
U.K.) supplemented with 10% fetal calf serum (Life 
Technologies, Paisley, U.K.) at 37 ºC in air with 5% 
CO2 and complete change of media every 2–3 days.
Cell viability and proliferation
Cell viability and proliferation was assessed in all 
cell lines after subjection to the various models. 
This was accomplished using a non-radioactive 
cell proliferation assay (Cell Titer 96 Aqueous 
Non-Radioactive Cell Proliferation Assay; 
Promega, U.K.). Absorbance of this product was 
measured by a photospectometer (Titertek 
Multiskan MKII, Titertek, U.K.) at 490 nm.
Co-culture assay
Mesothelial cells were seeded at a density of 1.5 × 106 
cells per well of a fl at-bottomed 24-well plates 
(Helena Bioscience, Sunderland, U.K.) in supple-
mented Media 199 with Earl’s salt and cultured to 
sub-confl uence. The media was then removed and 
the cells were washed twice with serum free media 
for 30 mins. Tumor cells were detached with non-
enzymatic cell dissociation solution (Sigma Chem-
ical Co., U.K.), and washed twice at 37 ºC in serum 
free media. Tumor cells (1.5 × 104 cells in 0.5 ml of 
serum free Media 199) were added to wells contain-
ing mesothelial cells, either in direct contact or 
separated by a 3.0 μm pore size fi lter (Corning 
Costar, U.S.A.) and incubated at 37 ºC for 24 hrs.
For inhibition studies, anti-ICAM and anti-CD43 
antibodies where included in the appropriate wells at 
a previously determined concentration of 
20 μgml–1 simultaneously with the tumor cells 
(Ziprin et al. 2004). In order to determine the effect 
of heparin on MMPs expression in the co-culture 
system, the assays were repeated with mesothelial 
cells which had been pre-treated with 100 iu/ml 
heparin (Alkhamesi et al. 2005b) and the tumor cells 
re-suspended in the same heparin containing 
medium. After 24 hrs, the supernatants were 
collected and levels of MMP-2 and MMP-9 
activity determined using gelatin zymography.
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Gelatin zymography
MMP-2 and MMP-9 activity of cell culture 
supernatants was determined as described by 
Aoudjit et al. (Aoudjit et al. 1997). Briefl y, super-
natant were centrifuged at 1200 rpm for 10 min 
to remove contaminating cells and debris, and the 
supernatants subjected to electrophoresis on a 
12% SDS-PAGE containing 1 mgml−1 gelatin. 
After electrophoresis, the gel was washed in 2.5% 
Triton X-100 to remove the SDS and incubated 
in developing buffer (50 mM Tris, 5 mM CaCl2 , 
0.02% NaN3, 1% Trion X-100) for 18 hrs at 37 oC. 
Lyric bands were visualized by staining with 
Coomassie brilliant blue and de-stained in 30% 
( v/v) methanol and 10% ( v/v) acetic acid. Quan-
titative analysis of activity was counted using 
computerized densitometry imager (Nonlinear 
Dynamic, Nonlinear U.S.A. Inc., U.S.A.).
Results
Mesothelial cells and tumor cells 
express MMP-2 and MMP-9
To establish a base line of MMP production in meso-
thelial and tumor cells, both groups were cultured 
separately to sub-confl uence in a suitable media as 
described in material and methods. The media was 
then changed into serum free media and the cells were 
grown for further 24 hrs. The supernatants were col-
lected and tested for MMP-2 and MMP-9.
MMP-2 expression was stronger in the z cell line 
in comparison to SW1222, P = 0.05. MMP-9 activity 
was also higher in mesothelial cell and almost negli-
gible in SW1222 cell line, P = 0.05 (Fig. 1).
Tumor-mesothelial cells interaction 
up-regulate MMPs expression
To study the effect of direct and indirect contact 
between mesothelial cells and colorectal tumor 
cells, both cell lines were co-cultured together for 
24 hrs either with direct contact or separated by a 
3.0 μm pore size fi lter. The supernatants were col-
lected and studied for MMP-2 and MMP-9 
productions.
Mesothelial cells showed constitutive expression 
of MMP-2, no significant up-regulation was 
observed when they were allowed indirect contact 
with tumor cells, however, noticeable increase in 
MMP-2 activity occurred when direct contact was 
initiated, P = 0.05. This was accompanied by the 
induction of MMP-9 activity P = 0.05 (Fig. 2). 
These data imply the role of direct contact in the 
initiation of protease production and therefore the 
possible involvement of cell adhesion molecules.
ICAM-1 and CD43 blockage attenuate 
tumor-mesothelial MMPs expression
We can see clearly from the previous results that 
tumor-mesothelial cells adhesion up-regulate 
MMP-2 and MMP-9 expression. We have also 
shown previously that this adhesion is ICAM-1 
dependent (Alkhamesi et al. 2005b). To investigate 
whether ICAM-1 and/or its ligand CD43 play a 
signifi cant role in MMPs production following the 
mesothelial-tumor cells co-culture, ICAM-1 
antibodies or CD43 antibodies were introduced to 
the co-culture and incubated for 24 hrs. The 
introduction of both sets of antibodies reduced 
MMP-2 and MMP-9 production in comparison to 
co-cultured cell lines without antibodies, P = 0.03 
and 0.02 respectively (Fig. 3).
Heparin down-regulate MMPs 
production following mesothelial-tumor 
cells interaction
The introduction of heparin to mesothelial-Tumor 
cells interaction has successfully blocked adhesion 
by down-regulating ICAM-1 expression (Alkhamesi 
et al. 2005b). We examined the possibility of 
introducing heparin to the tumor-mesothelial 
co-culture to attenuate MMPs production.
Heparin was added to the co-culture and the cell 
lines were incubated for further 24 hrs. The super-
natants were collected and a gelatin zymography 
was performed to measure MMP-2 and MMP-9 
production.
It is clear from Figure 4 that heparin introduc-
tion had decreased MMP2 and MMP-9 production 
in comparison to control co-culture, P = 0.04 and 
0.03 respectively.
Discussion
The productions of MMPs have been proposed as a 
mechanism by which tumor cells can penetrate and 
invade target tissue. They are up-regulated in almost 
every human cancer and usually associated with poor 
prognosis (Baker et al. 2006). MMPs function by 
cleaving a diverse group of substrates that include 
in addition to the structural components of the extra-
cellular matrix, growth-factor-binding proteins, 
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growth-factor precursors, receptor tyrosine kinases, 
and cell adhesion molecules (Egeblad and Werb, 
2002).
In previous studies, we showed that heparin could 
successfully down-regulate ICAM-1 production in 
vitro resulting in preventing tumor adhesion. Sub-
sequent tumor growth and metastases were 
significantly reduced in in vivo animal models 
(Alkhamesi et al. 2005b; Alkhamesi et al. 2005a). 
These in vivo data implied more than a simple one-
step block of adhesive function and suggested a 
possible role in the reduction of invasion capacity.
ICAM-1 has been shown to initiate malignant 
invasion in a number of malignancies via its 
interaction with apical MUC-1 on circulating tumor 
cells and this interaction can be enhanced by 
tumor cytokine activities (Roland et al. 2007). It 
also documented that inhibition of ICAM-1 
production by host and/or tumor cells can decrease 
MMP activity resulting in reduction of adhesion 
and subsequent invasion (Hyoudou et al. 2007)
In this study, we demonstrated that MMP-2 and 
MMP-9 are produced predominantly by mesothelial 
cells and their expression is up-regulated once there 
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Figure 1. Mesothelial and Tumor cells MMP expression. (a) Characteristic gelatin zymography indicating both mesothelial and colorectal 
tumor cells expression MMP2 and MMP9. Proteases activity is higher in the mesothelial cells. Each line indicates one of triplicate taken from 
either SW1222 or primary mesothelial cells. (b) Graph shows the results of minimum three experiments.
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is a contact between the mesothelial cells and the 
tumor cells. This up-regulation is more prominent with 
direct contact indicating the important role of cell 
adhesion molecules and subsequent signaling. These 
data also show the vital role that ICAM-1 plays not 
only in initiating tumor-mesothelium adhesion, but 
also in preparing the right environment for subsequent 
invasion despite some published data suggesting that 
the up-regulation of ICAM-1 inhibit tumor 
progression and indicate a better prognosis (Maeda 
et al. 2002; Tachimori et al. 2005)
Previously published data have shown 
bi-directional signaling during contact between 
tumor cells and target tissue, in particular 
lymphoma cells and the endothelial cells can result 
in high expression of MMP-2 and MMP-9 in both 
cell types (Aoudjit et al. 1997). These results are 
similar to what we have demonstrated in the current 
study in which the introduction of tumor cells into 
the co-culture triggered a higher expression of 
MMP-2 and MMP-9 via a bi-directional 
signaling.
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Figure 2. Mesothelial-Tumor cells interactions up-regulate MMP expression. (a) Representative gelatin zymography shows total MMP-2 and 
9 productions by mesothelial cells (A) and tumor Cells (B). Mesothelial cells in direct contact with tumor cells (C) and in. indirect contact with 
tumor cells (D). There is clear up-regulation of MMPs expression when the mesothelial cells were co-cultured with tumor cells. MMPs expres-
sion by tumor cells alone in negligible. (b) Graph indicating the results of minimum three experiment (Meso + FT = Mesothelial cell + Filter 
+ Tumor cells. Meso + T = Mesothelial cells + Tumor cells).
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Blocking this vital cell adhesion molecule 
(ICAM-1), by using inhibiting antibodies clearly 
reduced MMP-2 and MMP-9 production and offers 
possible new generation of therapeutics that can 
target both adhesion and invasion.
By applying heparin to this experimental design, 
we were able to achieve similar results to blocking 
ICAM-1 and CD43. These fi nding support our 
previous results and enforce the important role that 
heparin can play in the surgical management of 
intra-abdominal cancers to prevent loco-regional 
peritoneal metastases.
Conclusions
We have shown that bi-directional signaling between 
mesothelial and tumor cells is an important factor 
in generating cancer invasion and that ICAM-1/CD43 
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Figure 3. Blocking cell adhesion molecules decreases proteases expression. (a) Representative gelatin zymography shows MMP-2 and 9 
expressions by mesothelial cells (A) and tumor cells (B). This expression was up-regulated when both mesothelial and tumor cells co-cultured 
together (C). However, the introduction of anti-ICAM (D) and anti-CD43 (E) antibodies blocked this interaction. (b) Graph shows the results 
of minimum three experiments.
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Figure 4. Heparin reduces proteases production. (a) Representative gelatin zymography shows MMP-2 and 9 expressions by mesothelial 
cells (A) and tumor cells (D). Heparin down-regulate MMP-2 and 9 activities when it was introduced (B) in comparison to the standard co-
culture (C). (b) Graph indicating the results of minimum three experiments.
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interaction is vital to this phenomenon. We also 
confi rmed the role of heparin as a potential success-
ful therapeutic in preventing postoperative perito-
neal loco-regional metastases.
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